Skip to content
10-Q

Quarterly Report

ANAVEX LIFE SCIENCES CORP. AVXL

0001731122-25-001105

← back to feed
Filed
Aug 12, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Aug 12, 2025 85.89M sh
Shares Diluted Q3 2025 · Jun 30, 2025 85.38M sh
Shares Diluted Q3 2025 · Jun 30, 2025 85.09M sh
Shares Diluted Q3 2025 · Jun 30, 2024 84.54M sh
Shares Diluted Q3 2025 · Jun 30, 2024 83.02M sh
Operating Cash Flow Q3 2025 · Jun 30, 2025 −$30.44M
Operating Cash Flow Q3 2025 · Jun 30, 2024 −$24.15M
Cash And Equivalents Q3 2025 · Jun 30, 2025 $101.16M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $132.19M
Stockholders Equity Q3 2025 · Jun 30, 2025 $90.96M
Stockholders Equity Q3 2025 · Mar 31, 2025 $99.76M
Stockholders Equity Q3 2025 · Sep 30, 2024 $120.26M
Stockholders Equity Q3 2025 · Jun 30, 2024 $129.78M
Stockholders Equity Q3 2025 · Mar 31, 2024 $134.96M
Stockholders Equity Q3 2025 · Sep 30, 2023 $141.85M
Total Liabilities Q3 2025 · Jun 30, 2025 $11.47M
Total Liabilities Q3 2025 · Sep 30, 2024 $15.3M
Total Assets Q3 2025 · Jun 30, 2025 $102.43M
Total Assets Q3 2025 · Sep 30, 2024 $135.57M
Eps Diluted Q3 2025 · Jun 30, 2025 −$0.16
Eps Diluted Q3 2025 · Jun 30, 2025 −$0.43
Eps Diluted Q3 2025 · Jun 30, 2024 −$0.14
Eps Diluted Q3 2025 · Jun 30, 2024 −$0.38
Eps Basic Q3 2025 · Jun 30, 2025 −$0.16
Eps Basic Q3 2025 · Jun 30, 2025 −$0.43
Eps Basic Q3 2025 · Jun 30, 2024 −$0.14
Eps Basic Q3 2025 · Jun 30, 2024 −$0.38
Rd Expense Q3 2025 · Jun 30, 2025 $9.96M
Rd Expense Q3 2025 · Jun 30, 2025 $30.3M
Rd Expense restated Q3 2025 · Jun 30, 2024 $11.81M
Rd Expense restated Q3 2025 · Jun 30, 2024 $30.22M
Net Income Q3 2025 · Jun 30, 2025 −$13.24M
Net Income Q3 2025 · Jun 30, 2025 −$36.55M
Net Income Q3 2025 · Jun 30, 2024 −$12.21M
Net Income Q3 2025 · Jun 30, 2024 −$31.38M
Operating Income Q3 2025 · Jun 30, 2025 −$14.46M
Operating Income Q3 2025 · Jun 30, 2025 −$40.56M
Operating Income restated Q3 2025 · Jun 30, 2024 −$14.6M
Operating Income restated Q3 2025 · Jun 30, 2024 −$38.61M